TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of PD consistent with United Kingdom Brain Bank Criteria or the Movement Disorder Society Research Criteria for the Diagnosis of Parkinson's Disease, with bradykinesia and sequence effect being present, and prominent motor asymmetry (if no rest tremor).~2. Current treatment with levodopa.~3. Stable on levodopa and other study-approved medications for PD motor symptoms for at least four weeks prior to screening.~4. Clinically significant wearing-off / fluctuating symptomatology warranting treatment with ISD~5. Presence of apathy at baseline (LARS \> -22)~6. Living with adult informant~Exclusion Criteria:~Current or prior treatment with istradefylline. 2. History of Deep Brain Stimulation (DBS) surgery, ablative surgery (e.g., pallidotomy, thalamotomy, focused ultrasound, etc.), Duopa pump implantation, or other invasive intervention for Parkinson's disease symptoms. 3. Injury or concomitant health condition at screening that would preclude engagement in light physical activity. 10 4. Prior history of cerebrovascular accident (e.g., stroke or aneurysm) or seizure disorder (other than febrile seizures during childhood). 5. Dementia (MoCA\<22) 6. Psychotic symptoms that would raise concern for safe use of ISD, as indicated by domains A (delusions) and B (hallucinations) of the Neuropsychiatric Inventory (NPI), and defined as a score of ≥4 on either the A (frequency × severity) or B (frequency × severity) scales of the NPI. 7. Depressive mood symptoms at baseline likely to interfere with response to treatment (BDI-II\>19) 8. Active suicidal ideation within 1 year prior to Screening Visit as determined by a positive response to Question 4 or 5 on the C-SSRS. 9. Diagnosis or treatment for any central nervous system disorder other than Parkinson's disease that could be expected in the eyes of the investigator to impact ability to participate in study. 10. Contraindications / conditions that would preclude safe dosing of 40mg ISD 11. Change in medications for mood or anxiety within 6 weeks of enrollment or anticipation of change in medications for mood or anxiety during the 8-week study period. 12. Moderate or severe hepatic impairment. 13. Current treatment with strong CYP3A4 inhibitors 14. Current treatment with strong CYP3A4 inducers 15. Pregnant women are not able to participate due to unknown safety risks associated with ISD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: None

Study Arms:
- Patient (Type: None): istradefylline 40mg daily over 12 week period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent must be obtained before any assessment is performed.~* Patients who have completed LCZ696D2301 and are able to be safely enrolled into this study as judged by the investigator.~Exclusion Criteria:~* Patients who discontinued study drug treatment during LCZ696D2301 due to an event or intercurrent illness. Eligibility can be re-considered if the event has resolved and no longer represents a risk to the patient and the patient can safely tolerate the administration of LCZ696 per the investigator's assessment.~* Any medical condition that in the opinion of the investigator is likely to prevent the patient from safely tolerating LCZ696 or complying with the requirements of the study.~* Patients who have experience of angioedema event(s) which occurred and reported by the investigator during LCZ696D2301.~* Pregnant or nursing (lactating) women.~* Women of childbearing potential unless they are using highly effective methods of contraception.~Other protocol-defined inclusion/exclusion may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 (Type: EXPERIMENTAL): Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* IBS diarrhea~Exclusion Criteria:~* \< 18 years of age~* Pregnancy/breast feeding~* concomitant medications to reduce bowel function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Acute flexor tendon transection in zone 2 in digits 2, 3, 4, or 5 (diagnosed within 1 week after the injury)~* Age over 18~* Patient's willingness to participate in the study~Exclusion Criteria:~* Tendon transection within 8 mm of its distal insertion (requiring reinsertion)~* Soft-tissue loss, severe crush, fracture, palmar plate injury, patient requiring revascularization~* Cognitive impairment or other factors (prisoner, military serviceman) which may affect one's decision making~* Substance abuse~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Amniotic membrane allograft group (Type: EXPERIMENTAL): After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proved diagnosis of locally advanced recurrent or metastatic non-squamous NSCLC that is not suitable for local curative treatment.~* Alk-positive NSCLC as determined by a test that is approved or validated for use as a companion diagnostic test.~* No prior systemic therapy for metastatic disease.~* Adjuvant chemotherapy more than 12 months prior to study enrollment.~* Measurable disease as per RECIST 1.1~* ECOG PS 0 or 1.~Exclusion Criteria:~* Prior exposure to ALK receptor tyrosine kinase inhibitor, anti-PD1, anti-PDL1 or any drug targeting T-cell checkpoint pathways.~* known diagnosis of immunodeficiency or is receiving systemic steroid therapy or other form of immunosuppressive therapy within 7 days of clinical trial treatment.~* Active autoimmune disease that has required systemic treatment in the past 3 months.~* History of extensive disseminated interstitial fibrosis or any grade of interstitial lung disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose finding and dose expansion phases (Type: EXPERIMENTAL): Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Natrecor in Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 18 to 85 years old.~2. Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's).~3. PHTN documented by Doppler Echocardiography ( Done with in last 30 days)~4. Must be able to give an informed consent.~Exclusion Criteria:~1. Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) \<90).~2. Active infection or sepsis as defined by fever and need for IV antibiotics.~3. Creatinine greater than 3.0 mg/dl~4. Significant valvular disease as a cause for the PHTN.~5. Severe Thrombocytopenia (as defined by platelets less than 20,000 or INR \> 1.6.~6. Left Ventricle Ejection Fraction (LVEF) \<40% (must be done with in the last 30 days prior to signing consent).~7. Hypersensitivity to nesiritide or any of it's components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nesiritide (Type: EXPERIMENTAL): Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Preoperative Oral Rehydration Solution in Colectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA grade I\~II (DM, CVA, COPD, ESRD, MI, TIA etc. excluded)~* Age: adults age 19\~75~* Patients undergoing elective colon cancer surgery~* Able to take the ORS per orally. Able to swallow without trouble of aspiration tendencies~* BMI of less than 27.5~* Child-Turcotte-Pugh Classification score of less than 6~Exclusion Criteria:~* emergency cases such as obstruction or perforation~* food allergy~* abdominal distension at present~* prior gastric surgery

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ORS group (Type: EXPERIMENTAL): Oral rehydration solution (ORS) treated group
- Non-ORS group (Type: NO_INTERVENTION): Oral rehydration solution (ORS) untreated group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female, 18 years old or older.~* Have been receiving chronic hemodialysis therapy~* On stable EPO dosing regimen.~* Have signed patient informed consent.~* Predetermined serum ferritin and TSAT levels.~* Clinical instability - inability to achieve adequate dialysis, abnormal serum albumin and serum glucose.~* Pregnant or lactating.~* A known sensitivity to Ferrlecit~Exclusion Criteria:~* Scheduled for renal transplant.~* A serious concomitant medical disorders incompatible with participation in the study.~* Unable to cooperate or comply with the protocol.~* Use of any investigation agent within 30 days prior to study or during the course of the study.~* Judged by the investigator as unsuitable for enrollment for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Oral Iron
- 2 (Type: EXPERIMENTAL): sodium ferric gluconate
- 3 (Type: EXPERIMENTAL): sodium ferric gluconate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Mobile Technology to Prevent Progression of Pre-hypertension in Latin American Urban Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Systolic blood pressure values in the 120-139 mmHg range or diastolic blood pressure in the 80-89 mmHg range~* No current anti-hypertensive medication~* Own a personal cellular phone~Exclusion Criteria:~* Previous diagnosis/treatment hypertension~* Illiteracy~* Another household member already in the study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Pre-hypertensive subjects who receive mHealth support for 12 months
- Control (Type: NO_INTERVENTION): Individuals who receive the usual primary health care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Of RV-39 In Patients Who Also Have Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have asthma for at least 3 months prior to the study.~* Have been using an allowed pre-study asthma therapy for at least 3 months prior to study.~* Demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor.~* Have a positive allergic status antibody test.~Exclusion Criteria:~* Have a history of life-threatening asthma.~* Been hospitalized for asthma within the 24 months prior to the study.~* Have certain conditions that would make study participation unsafe.~* The study doctor will evaluate other inclusion and exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None
- Arm 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Prediction Rule for Clinical Lumbar Instability

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. duration of the current episode of low back pain less than 3 months,~2. average pain intensity over past 3 days at least 4 on an 11 point (0 = no pain, 10 = worst pain ever) numeric pain rating scale,~3. no medical intervention for low back pain in last 6 months,~4. Oswestry score greater than 25%~Exclusion Criteria:~1. permanent structural spinal deformity (e.g., scoliosis)~2. history of spinal fracture or diagnosis of osteoporosis~3. diagnosis of inflammatory joint disease~4. signs of systemic illness or suspected non-mechanical LBP (i.e. spinal tumor or infection)~5. previous spinal surgery~6. frank neurological loss, i.e., weakness and sensory loss~7. history of neurologic disease that required hospitalization,~8. active treatment of another medical illness that would preclude participation in any aspect of the study or any lower extremity injury that would potentially alter trunk movement in standing~9. leg length discrepancy of greater than 2.5 cm.~10. pregnancy~11. vestibular dysfunction

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low back pain (Type: OTHER): Individuals with current low back pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Inhaled N-Acetylcysteine Compared to Normal Saline on Sputum Rheology and Lung Function

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who can perform lung function tests and who can produce sputum (\> 5 years of age)~* (Fe)males between 6-64 years~Exclusion Criteria:~* Patients on the waiting lists for lung transplant.~* Pregnancy or breast feeding~* Patients can not take part in another 'inhalation'trial for Cystic Fibrosis

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Acetylcysteine (Type: EXPERIMENTAL): Inhalation with N-Acetylcysteine
- normal saline (Type: PLACEBO_COMPARATOR): Inhalation with normal saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ambulatory ECG Telemetry for the Early Detection of Atrial Fibrillation During Hospital Assessment of Cerebral Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old~* Diagnosis of transient ischemic or cerebral accident~* Absence of etiological orientation after the initial assessment (including at least cerebral MRI, angiography of the supra aortic trunks by CT or MRI, echocardiography with search for patent foramen ovale, standard biology)~* Affiliated to a social security system.~* Having given no opposition to participation in research~Exclusion Criteria:~* AF known or diagnosed during stay in USINV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- holter-ECG (Type: EXPERIMENTAL): Implementation of an ECG Holter during hospitalisation patient.
- Crontrole (Type: NO_INTERVENTION): No implementation of an ECG Holter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sleep and Pain Sensitivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women presenting with an apnea-hypopnea (AHI) index \> 15 (moderate-to-severe sleep apnea) measured by cardiorespiratory monitoring (CRM) and scheduled for treatment at Søvncenter Nord~* Age 18-80~Exclusion Criteria:~* Pregnancy~* Intake of drugs labelled with the red warning triangle and misuse of cannabis and opioids~* No previous or current neurologic or mental illnesses~* Lack of ability to cooperate~* Non-fluent in Danish (reading, speaking, and comprehension)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sleep apnea patients (Type: None): This group of patients will have been monitored over night with cardiorespiratory monitoring (CRM). CRM enables the physician to establish an Apnea-Hypopnea Index (AHI) which will be used for diagnosis. An AHI \> 15 is considered moderate-to-severe sleep apnea, and this is the focus group of patients in the current project.~These patients will be followed for 12 months during continuous positive airway pressure (CPAP) treatment. Adherence to the CPAP treatment will be closely monitored.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy~2. Anticipation that the patient will be followed by the participating center at least for the next 12 months~3. Diagnosis of UC must be established on the basis of standard clinical, radiographic, endoscopic, and histologic criteria as described below.~Exclusion Criteria:~* 1. Patients will be excluded if they meet any of the following criteria:~  1. Inability to provide informed consent~ 2. Patients presenting for a one-time consultation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib (Type: None): Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on tofacitinib therapy for moderate to severe UC or who plan to start this therapy within the next 2 weeks. The start of the tofacitinib therapy must have been or be initiated in the setting of standard of care therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues